Vontobel Holding Ltd. Takes $400,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Vontobel Holding Ltd. purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,691 shares of the medical research company’s stock, valued at approximately $400,000.

Other hedge funds have also modified their holdings of the company. VisionPoint Advisory Group LLC increased its stake in Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $37,000. Operose Advisors LLC purchased a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $42,000. Venturi Wealth Management LLC increased its stake in Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 112 shares in the last quarter. Finally, Provence Wealth Management Group purchased a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $57,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 3.2 %

Shares of CRL opened at $239.98 on Wednesday. The stock’s 50-day moving average is $254.27 and its two-hundred day moving average is $222.23. The stock has a market cap of $12.36 billion, a PE ratio of 26.06, a P/E/G ratio of 1.78 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm’s quarterly revenue was down 7.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.98 earnings per share. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CRL. UBS Group raised their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Argus raised their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, March 18th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. JPMorgan Chase & Co. lifted their target price on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Finally, Evercore ISI lifted their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $253.23.

Insider Transactions at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).